We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 00:00:00 |
From Feb 2020 to Feb 2025
Biocon Ltd. (532523.BY) said Monday it has signed a pact with Mylan Inc. (MYL) to collaborate on developing, making and selling generic versions of biologic drugs for the global market.
Biologic, or biopharmaceutical, drugs are synthesized from living organisms for medical use.
As part of the collaboration, Mylan and Biocon will share the development, capital and other costs to bring products to the market, the Indian biopharmaceutical company said in a statement.
Mylan will have exclusive marketing rights in the U.S., Canada, Japan, Australia, New Zealand and in the European Union and the European Free Trade Association countries through a profit-sharing agreement with Biocon.
Mylan will share marketing rights with Biocon in all other markets around the world.
The company didn't provide any other financial terms or product details.
-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
